• Fri news: Pfizer’s $1B Chinese commitment. RFK Jr. and pharma. Eisai dials back Leqembi forecast. US diabetes burden increase. JNJ gets Varipulse approval. See more on our front page

Annette Powers… doomed leader

Quote
anonymous said:
I'm not sure who Miachel (or you probably meant Michael) is.....but I can assure you, I am not him. Not brown nosing, truth telling, even though people seem to not want to hear anything other than their own perceptions.....BMS has an access issue that many of us (Celgene/BMSers) understand from our previous histories; Adam, Chris B, Steve P (no longer here) etc - have no clue. Blockbusters like Opdivo, Eliquis, Orencia - don't teach you about what an access strategy needs to be to WIN. Hence Zeposia UC being dismantled and Sotyktu having a hard access climb. MAx can't work miracles in a market so competitive with unrealistic expectations. Many factors go into it, pricing, competition, biosimilars, and contracting (aka rebate walls) to name a few. We have to set realistic expectations, appropriate pricing, train the sales force on PUSH through tactics when access isn't there and PULL through tactics when it is, the HUB has to work flawlessly, etc. When the company overall doesn't want to train the sales teams on market access and only on clinical attributes - Houston, we have a problem, when there is no access due to market conditions. Annette knows way more about all of this - because she's lived it outside of BMS - than senior leadership. Yes, she's direct. Yes, she speaks her mind. I wish more people would do that so this organization could THRIVE during this trying time instead of SURVIVE. We keep making the same wrong decisions and expecting a different result.
Click to expand...
Ok. Now put your head back up her a$$ stink boy.
 




anonymous said:
I'm not sure who Miachel (or you probably meant Michael) is.....but I can assure you, I am not him. Not brown nosing, truth telling, even though people seem to not want to hear anything other than their own perceptions.....BMS has an access issue that many of us (Celgene/BMSers) understand from our previous histories; Adam, Chris B, Steve P (no longer here) etc - have no clue. Blockbusters like Opdivo, Eliquis, Orencia - don't teach you about what an access strategy needs to be to WIN. Hence Zeposia UC being dismantled and Sotyktu having a hard access climb. MAx can't work miracles in a market so competitive with unrealistic expectations. Many factors go into it, pricing, competition, biosimilars, and contracting (aka rebate walls) to name a few. We have to set realistic expectations, appropriate pricing, train the sales force on PUSH through tactics when access isn't there and PULL through tactics when it is, the HUB has to work flawlessly, etc. When the company overall doesn't want to train the sales teams on market access and only on clinical attributes - Houston, we have a problem, when there is no access due to market conditions. Annette knows way more about all of this - because she's lived it outside of BMS - than senior leadership. Yes, she's direct. Yes, she speaks her mind. I wish more people would do that so this organization could THRIVE during this trying time instead of SURVIVE. We keep making the same wrong decisions and expecting a different result.
Click to expand...
This has someone from Sotyktu US Access written all over it. Must be the lady with the funny face. They literally destroyed this brand with untimely access. They should be fired ASAP. And Powers is not direct….she is dubious and dumb.
 








Look at the long list of market access leader's who have left in the last 2 years. Mike, Allen, Eric, Stephen, Diane, Chris V, Jane, Tom, Fred, Chris M, John O, Arran and the latest Katherine. Are you surprised Mike is on this list? U shouldn't be. He was the first to get fed up and leave. Ask all the companies he is consulting for, he is not retired.

Any bets on who is next to hit the exit?
 




anonymous said:
Look at the long list of market access leader's who have left in the last 2 years. Mike, Allen, Eric, Stephen, Diane, Chris V, Jane, Tom, Fred, Chris M, John O, Arran and the latest Katherine. Are you surprised Mike is on this list? U shouldn't be. He was the first to get fed up and leave. Ask all the companies he is consulting for, he is not retired.

Any bets on who is next to hit the exit?
Click to expand...
Some of these were complete douches. You and they know who they are.
 




anonymous said:
Look at the long list of market access leader's who have left in the last 2 years. Mike, Allen, Eric, Stephen, Diane, Chris V, Jane, Tom, Fred, Chris M, John O, Arran and the latest Katherine. Are you surprised Mike is on this list? U shouldn't be. He was the first to get fed up and leave. Ask all the companies he is consulting for, he is not retired.

Any bets on who is next to hit the exit?
Click to expand...
Next=Frank? He’s a good guy, and good ones aren’t staying at BMS anymore in access. True about Mike R. -I heard he out-thought Lurch so they didn’t mesh well.
 








anonymous said:
Next=Frank? He’s a good guy, and good ones aren’t staying at BMS anymore in access. True about Mike R. -I heard he out-thought Lurch so they didn’t mesh well.
Click to expand...
Outthinking Lurch is not that difficult. A nutless monkey could do it. Unfortunately Powers is a ding dong dumb belle. But Lurch likes her. Surprised she has not been appointed yet.
 








Just wait until we deprioritize Sotyktu next quarter. Non-promoted or divested. Call it what you want. There will be no growth even with the new access situation. No one supported this decision yet Lurch pushed it through because he knew it was the right decision. And he owns the keys to the castle. He mortgaged this company. Yet he is not held accountable. No one supported this decision and now we are in trouble. Look for another massive reorganization in January. Good god this place is a mess.
 




So word from reliable source is that Access fiction is going to be split up. VP of Access for Cell Tx is moving under Lynelle. More split ups coming soon. Access is getting dissected.
 








































Top Bottom
Back
Quote